Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Unaudited Condensed Interim Consolidated Statements of Cash Flows

v3.20.2
Unaudited Condensed Interim Consolidated Statements of Cash Flows - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Operating activities:        
Net loss for the period $ (1,143,199) $ (14,472,866) $ (1,911,242) $ (42,755,746)
Items not involving cash:        
Amortization 35,475 7,291 49,570 13,466
Stock based compensation 206,087 740,051 434,663 991,408
Warrant liability-fair value adjustment 8,782,920 (6,609,952) 7,665,444 3,866,673
Warrant liability-foreign exchange adjustment 12,997 142,682 (38,094) 36,625
Non-cash issue costs 737,894   764,134
Non-cash settlement included in payables 1,839,626 2,090,200
Non-cash note payable expenses and accrued interest 153,822 153,822
Changes in non-cash working capital items:        
Amounts receivable, prepaid expenses and deposits (766,837) 1,294,599 (593,417) (283,330)
Accounts payable and accrued liabilities (3,647,795) 5,736,133 (4,875,714) 5,783,889
Cash from (used) in operating activities 6,210,990 (13,162,062) 3,739,366 (32,347,015)
Financing activities:        
Net proceeds from issuance of common shares and warrants [1] 19,272,277 (2,997) 22,749,702 31,374,911
Proceeds from note payable 1,500,000 1,500,000
Repayment of lease liabilities (6,299) (10,243)
Cash provided by financing activities 20,765,978 (2,997) 24,239,459 31,374,911
Investing Activities:        
Additions of patents (47,430) (125,198) (103,560) (178,956)
Cash used in investing activities (47,430) (125,198) (103,560) (178,956)
Increase (Decrease) in cash and cash equivalents 26,929,538 (13,290,257) 27,875,265 (1,151,060)
Cash and cash equivalents, beginning of the period 1,760,219 23,610,440 814,492 11,471,243
Cash and cash equivalents, end of the period 28,689,757 10,320,183 28,689,757 10,320,183
Cash and cash equivalents comprise:        
Cash 970,690 1,392,741 970,690 1,392,741
Cash Equivalents 27,719,067 8,927,442 27,719,067 8,927,442
Cash and cash equivalents, end of the period $ 28,689,757 $ 10,320,183 $ 28,689,757 $ 10,320,183
[1] Includes net proceeds from the issuance of common share equivalents (see note 8a)